Cubist shares appear oversold, says RBC Capital

After Hospira (HSP) announced that it may be able to apply for FDA approval of its version of Cubist's (CBST) Cubicin, RBC Capital believes this overhang on Cubist is "addressable." The firm believes that Cubist's fundamentals are solid and it maintains a $53 price target and Outperform rating on Cubist.

View Comments (0)